Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN‐λ and elevated secretion of Cxcl10
Open Access
- 16 May 2013
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 5 (7) , 1035-1050
Abstract
The theory of cancer immunoediting refers to mechanisms by which the immune system can suppress or promote tumour progression. A major challenge for the development of novel cancer immunotherapies is to find ways to exploit the immune system's antitumour activity while concomitantly reducing its protumour activity. Using the PyVmT model of mammary tumourigenesis, we show that lack of the Usp18 gene significantly inhibits tumour growth by creating a tumour‐suppressive microenvironment. Generation of this antitumour environment is driven by elevated secretion of the potent T‐cell chemoattractant Cxcl10 by Usp18 deficient mammary epithelial cells (MECs), which leads to recruitment of Th1 subtype CD4 + T cells. Furthermore, we show that Cxcl10 upregulation in MECs is promoted by interferon‐λ and that Usp18 is a novel inhibitor of interferon‐λ signalling. Knockdown of the interferon‐λ specific receptor subunit IL‐28R1 in Usp18 deficient MECs dramatically enhances tumour growth. Taken together, our data suggest that targeting Usp18 may be a viable approach to boost antitumour immunity while suppressing the protumour activity of the immune system.Keywords
Funding Information
- National Institutes of Health (HL091549 to DEZ)
This publication has 54 references indexed in Scilit:
- Two Independent Mechanisms Promote Expression of an N-terminal Truncated USP18 Isoform with Higher DeISGylation Activity in the NucleusJournal of Biological Chemistry, 2012
- IL‐28A (IFN‐λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway diseaseEMBO Molecular Medicine, 2011
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancerNature Communications, 2011
- CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancerBreast Cancer Research and Treatment, 2010
- Impaired interferon signaling is a common immune defect in human cancerProceedings of the National Academy of Sciences, 2009
- Spontaneous tumor rejection by cbl-b–deficient CD8+ T cellsJournal of Experimental Medicine, 2007
- Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient miceTransgenic Research, 2007
- UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activityThe EMBO Journal, 2006
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002